Notably, beyond the selective iNOS inhibitor SMT and the pan-NOS inhibitor L-NAME used in our study, at least 14 other NOS inhibitors with greater isoform selectivity, particularly toward iNOS, have been evaluated in various in vitro and in vivo CRC models (Wang et al., 2020). This evidence concerns the gene NOS1 and colorectal carcinoma.